Insights
Search Results
Client Highlights
12.16.25
Wilson Sonsini Advises Arthrosi Therapeutics on on Patent Matters Related to its Acquisition by Sobi
On December 13, 2025, Sobi announced it has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc., a private late-stage biotechnology company focused on developing a next-generation treatment for gout. Sobi will pay $950 million upfront in cash and up to $550 million in cash in clinical, regulatory and sales milestones. Wilson Sonsini Goodrich & Rosati represented Arthrosi Therapeutics on patent matters related to the acquisition.
Client Highlights
9.18.24
Wilson Sonsini Advises Neo Medical SA on Series B and $68 Million Equity Investment
On September 17, 2024, Neo Medical SA (Neo), a Swiss technology company specializing in spine surgery, announced the successful completion of its Series B financing round, including the conversion of existing shareholder loans. With this financing round, Neo has secured an additional equity investment of up to $68 million to accelerate its global growth. Led by Gyrus Capital SA (Gyrus), alongside the participation of existing investors, including founders Vincent Lefauconnier and Jonas Larsson, this round is one of the most significant in the spine industry in the last decade. The proceeds will be used to increase Neo’s market share in key regions with an immediate focus on expanding the U.S. business, deploying new, complementary, and disruptive products, and enhancing the capabilities of its unique AIdriven augmented reality intraoperative data platform, ADVISE™.
Client Highlights
9.17.24
Wilson Sonsini Advises MBX Biosciences on Patents Matters Related to IPO
On September 16, 2024, MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, announced the closing of its upsized initial public offering. The aggregate gross proceeds from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on patent matters related to the upsized IPO.
Client Highlights
8.09.24
Wilson Sonsini Advises Recursion on Definitive Agreement with Exscientia
On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Client Highlights
8.06.24
Firm Advises MBX Biosciences on Patent Matters Related to $63.5 Million Series C Financing
On August 5, 2024, MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, announced a $63.5 million Series C financing. The financing was led by Deep Track Capital, with participation from new investors Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc., as well as existing investors Frazier Life Sciences, OrbiMed, and Wellington Management, complementing the company’s existing investor base, including New Enterprise Associates (NEA), Norwest Venture Partners, and RA Capital Management. Wilson Sonsini Goodrich & Rosati represents MBX Biosciences on patent matters, and advised the company on patent matters related to this Series C financing.
The proceeds from the transaction are expected to support MBX Biosciences into 2026 and past key data read-outs from the company’s pipeline. The Phase 2 clinical trial of MBX 2109, the company’s parathyroid hormone peptide prodrug, in patients with hypoparathyroidism was recently initiated and topline results are expected in the third quarter of 2025. MBX 1416, the company’s product candidate for post-bariatric hypoglycemia, is currently being evaluated in a Phase 1 single and multiple ascending dose trial, which is expected to report topline data in the fourth quarter of 2024. MBX also has a portfolio of early-stage candidates in obesity and metabolic disease, including MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug currently in IND-enabling studies.
The Wilson Sonsini team was led by Uale Taotafa and included Nima Zargari, Jose Martinez, T.J. O’Connor, and Mike Hostetler.
For more information, please see MBX Biosciences’ news release.
The proceeds from the transaction are expected to support MBX Biosciences into 2026 and past key data read-outs from the company’s pipeline. The Phase 2 clinical trial of MBX 2109, the company’s parathyroid hormone peptide prodrug, in patients with hypoparathyroidism was recently initiated and topline results are expected in the third quarter of 2025. MBX 1416, the company’s product candidate for post-bariatric hypoglycemia, is currently being evaluated in a Phase 1 single and multiple ascending dose trial, which is expected to report topline data in the fourth quarter of 2024. MBX also has a portfolio of early-stage candidates in obesity and metabolic disease, including MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug currently in IND-enabling studies.
The Wilson Sonsini team was led by Uale Taotafa and included Nima Zargari, Jose Martinez, T.J. O’Connor, and Mike Hostetler.
For more information, please see MBX Biosciences’ news release.